Popular terms

Bowel topics
Bowel Disease
Inflammatory Bowel Disease
Irritable Bowel Syndrome
Inflammation
Mercaptopurine
Probiotics
Abdominal Pain
Discomfort
Bowel Movement
Gastrointestinal
Ulcerative Colitis
Rheumatoid Arthritis
Jejunal Tube
Spring Mechanism
Small Bowel

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Bowel patents



      

This page is updated frequently with new Bowel-related patent applications.




Date/App# patent app List of recent Bowel-related patents
06/23/16
20160178644 
 Methods for diagnosing and treating inflammatory bowel disease patent thumbnailnew patent Methods for diagnosing and treating inflammatory bowel disease
Biomarkers for diagnosing inflammatory bowel disease, including crohn's disease, including fibrotic or fibrostenotic crohn's disease, and ulcerative colitis and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and crohn's disease, including fibrotic or fibrostenotic crohn's disease, are provided..

06/23/16
20160177306 
 Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field patent thumbnailnew patent Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
The invention relates to antisense oligonucleotidic sequences (odn) against smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as crohn's disease and ulcerative colitis.. .

06/23/16
20160176816 
 Novel biphenyl derivative and  preparing same patent thumbnailnew patent Novel biphenyl derivative and preparing same
The present invention provides novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, methods for preparing the same, and a pharmaceutical composition containing the same. The novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, as disclosed in the present invention, act as muscarinic m3 receptor antagonists, and thus are useful for the prevention or treatment of a disease selected from the group consisting of chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes..

06/23/16
20160175491 
 Local drug delivery devices and methods for treating cancer patent thumbnailnew patent Local drug delivery devices and methods for treating cancer
Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site..

06/23/16
20160175382 
 Compositions and methods for inducing urinary voiding and defecation patent thumbnailnew patent Compositions and methods for inducing urinary voiding and defecation
Methods, pharmaceutical formulations, and kits are provided for using neurokinin 2 receptor agonists to effectuate voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing voiding of urine and defecation in mammals that do not have a voiding dysfunction such as, for example, in a person who is comatose and may void unconsciously or in a pet at a convenient location at a specific time.

06/23/16
20160175368 
 Legume/grain based food product with prebiotic/probiotic source patent thumbnailnew patent Legume/grain based food product with prebiotic/probiotic source
A minimally processed ready-to-eat legume/grain product is provided containing a significant amount of probiotic fiber and a probiotic source or is consumed with a probiotic source for the prevention and/or treatment of inflammatory chronic conditions such as inflammatory, autoimmune chronic conditions such as irritable bowel syndrome (ibs), digestive disorders such chronic constipation, gastric acid reflux, diabetes, heart disease, obesity, some type of cancer, malabsorptive disorders, eczema as well mental health disorders such as anxiety disorder. The present invention is suitable for men and woman of all ages..

06/23/16
20160175253 
 Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and  preparation thereof patent thumbnailnew patent Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and preparation thereof
The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.. .

06/16/16
20160168201 
 Methods and compositions for the treatment of gastrointestinal disorders patent thumbnailMethods and compositions for the treatment of gastrointestinal disorders
Compositions and related methods for treating ibs and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (gerd), duodenogastric reflux, crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase c (gc-c) receptor..
Ironwood Pharmaceuticals, Inc.


06/16/16
20160166602 
 Food supplement composition patent thumbnailFood supplement composition
A dietary supplement for promoting increased vitality, supporting mood, improving heart health, improving immune strength, improving antioxidant balance, protecting against free radical damage, improving bowel function, and enhancing flavonoid intake. The composition is a combination of cacao, chia seeds, green tea, cinnamon, ginger and turmeric in specific percents of the formulation.
Homeland Housewares, Llc


06/16/16
20160166599 
 Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient patent thumbnailTherapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient
The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine n1-oxide or a derivative thereof as an effective ingredient.. .
Hayashibara Co., Ltd.


06/16/16
20160166587 

Amelioration of intestinal fibrosis and treatment of crohn's disease


Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or crohn's disease involve administering a therapeutic amount of card-024 or related compound.. .
The Regents Of The University Of Michigan


06/16/16
20160166576 

Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)


This invention relates to amidopyrazole compounds that are inhibitors of interieukin receptor-associated kinases, in particular irak-4, and are useful in the treatment of cellular proliferative diseases. Speifically (5-methylpyridin-2-yl)-1 h-pyrazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives are disclosed for use in the method of treating inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and cancer..
Merck Sharp & Dohme Corp.


06/09/16
20160161503 

Diagnostic method


The invention relates to a method of diagnosing or assessing an inflammatory bowel disease in a subject, comprising comparing the level of one or more markers in a tissue or body fluid of the subject relative to a reference value for the one or more markers, wherein the marker is selected from the group consisting of secretogranin-1 or a fragment thereof, guanylin or a fragment thereof, spp 24 or a fragment thereof, ambp or a fragment thereof; and serglycin or a fragment thereof.. .
Sydney Local Health District


06/09/16
20160161501 

Novel inflammatory bowel disease markers and therapies for colitis-associated intestinal fibrosis


Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof.
The Regents Of The University Of California


06/09/16
20160159790 

Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof


This invention concerns pyrroloquinoline derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, parkinson's disease, huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, irritable bowel syndrome.
Universite De Montpellier


06/09/16
20160158303 

Method of extracting flavonoids and/or polyphenols from dried and powdered citrus peels, compositions therefrom, and methods of treatment of diseases associated with chronic inflammation


Improved processes for extracting polyphenols and/or flavonoids from citrus peels are provided that comprise 1) heating a ground peel to form a pre-treated, ground peel; and 2) extracting the compounds of interest from the pre-treated, ground peel using a basic solution of ph greater than 7 and less than 12. Such processes serve to increase the efficiency of extraction of the polyphenols and/or flavonoids.
Tait Laboratories Inc.


06/09/16
20160158262 

Methods of treating irritable bowel syndrome


The present invention provides a method for treating irritable bowel syndrome (ibs) in a subject in need thereof. The treatment can include administering about 550 mg of rifaximin three times per day and about 500 mg of neomycin two times per day for 14 days to the subject to treat the ibs.
Cedars-sinai Medical Center


06/02/16
20160153041 

Detection and treatment of irritable bowel syndrome


Methods are disclosed herein for identifying a subject with irritable bowel syndrome (ibs). Methods are also disclosed for determining if an agent is effective for the treatment or prevention of ibs.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


06/02/16
20160152699 

Pan-elr+ cxc chemokine antibodies


Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company


06/02/16
20160151449 

Use of tight junction antagonists to treat inflammatory bowel disease


The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents.
Alba Therapeutics Corporation


06/02/16
20160151340 

Bowel cleansing composition


A bowel cleansing composition includes as a first cleansing ingredient, a specific sugar alcohol such as xylitol, sorbitol, etc., as a second cleansing ingredient glycerol, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, and polyglycitol, as a second cleansing ingredient ascorbic acid or a mixture of ascorbic acid and a salt of ascorbic acid, as a third cleansing ingredient picosulfate, and an aqueous solvent, wherein the concentration of the first cleansing ingredient is 10 g/l to 500 g/l based on the total composition, the concentration of the second cleansing ingredient is 15 g/l to 500 g/l based on the total composition, the concentration of the third cleansing ingredient is 1 mg/l to 100 mg/l based on the total composition, and the volume of the aqueous solvent is 0.1 l to 1.0 l.. .

05/26/16
20160145694 

Method for detecting methylation of colorectal cancer specific methylation marker gene for colorectal cancer diagnosis


The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker gpm6a (nm_201591, glycoprotein m6a) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis..
Genomictree, Inc.


05/26/16
20160145306 

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases


The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease.. .
Protagonist Therapeutics, Inc.


05/26/16
20160145289 

Compounds and methods for treating bacterial infections


The present invention encompasses compounds and methods for treating and preventing bacterial infections specifically urinary tract infections and those caused by bacteria containing type 1 pili and fimh. The present invention also encompasses compounds and methods for treating inflammatory bowel disease specifically crohn's disease..
Washington University


05/26/16
20160145249 

Alxr agonist compound


The present invention provides a compound having alxr agonist activity. Specifically, the invention provides a compound having alxr agonist activity represented by general formula (i) wherein all the symbols are as defined in the specification, a salt thereof, a solvate thereof, or a prodrug thereof as well as an agent containing the same as an active ingredient for preventing and/or treating an alxr-associated disease, such as an inflammatory bowel disease, an autoimmune disease, a chronic inflammatory disease, asthma, pulmonary fibrosis, atopic dermatitis, ischemia-reperfusion injury, myocardial infarction, or alzheimer's disease..
Ono Pharmaceutical Co., Ltd.


05/26/16
20160145206 

N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use


The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (copd); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as behçet's disease.
Pimco 2664 Limited


05/26/16
20160143965 

Bacteriophage therapy


The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive escherichia coli strain thereby treating the subject.
Institut Pasteur


05/26/16
20160143940 

Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems


Psa is delivered to the host by outer membrane vesicles (omvs), secretion structures that target bacterial molecules to host cells. Purified omvs direct the in vitro differentiation of functional tregs with potent suppressive activity in a psa dependent manner.
California Institute Of Technology


05/26/16
20160143723 

Implantable digestive tract organ


An implantable digestive organ is provided for the transport of materials through the digestive tract and in one particular application to an artificial large bowel for replacing all or part of a colon. The prosthetic organ of one embodiment includes an outer support structure, an expandable member or members located within the support structure, and a flexible inner member forming a conduit for passage of material.
Python Medical, Inc.


05/19/16
20160139148 

Pathway specific markers for diagnosing irritable bowel syndrome


The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (ibs) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (ibd), and has ibs and/or a subtype thereof.
Nestec S.a.


05/19/16
20160139123 

Shear wave imaging method and installation for collecting information on a soft solid


The invention relates to methods comprising a step consisting of determining the proportion and/or the level of t regulatory lymphocytes with a cd4+ cd8ααlow foxp3neg phenotype specific for faecalibacterium prausnitzii for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing, an inflammatory bowel disease in a patient. The invention also concerns the treatment of an inflammatory bowel disease.
Assistance Publique - Hopitaux De Paris


05/19/16
20160137613 

Novel anti-inflammatory agents


Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (il-6) and/or vascular cell adhesion molecule-1 (vcam-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation..
Resverlogix Corp.


05/19/16
20160136420 

Electrical stimulation to inhibit bladder and/or bowel contraction


In one example, a method including generating electrical stimulation therapy with a frequency of approximately 500 hertz or greater, and controlling delivery of the electrical stimulation therapy to a patient via a medical device between at least one of contractions of a bladder or contractions of a bowel of a patient, wherein the electrical stimulation therapy comprises electrical stimulation therapy configured to inhibit contraction of the bladder when the electrical stimulation is delivered between the contractions of the bladder, wherein the electrical stimulation therapy comprises electrical stimulation therapy configured to inhibit contraction of the bowel when the electrical stimulation is delivered between the contractions of the bowel, and wherein at least one of the generating and controlling is performed via one or more processors.. .
Medtronic, Inc.


05/19/16
20160135813 

Occluder and anastomosis devices


An implantable medical device for sealing and repairing defects in a body tissue or for creating an anastomosis includes a frame and a covering material. In some embodiments, the frame includes a single continuously wound wire that defines an apposition portion, a defect-occupying portion, and a sealing portion.
W. L. Gore & Associates, Inc.


05/12/16
20160130279 

Pathway specific assays for predicting irritable bowel syndrome diagnosis


The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful reagents for specific and sensitive immunoassays the present invention also provides stable derivatives of various metabolites and short chain fatty acids.
Nestec S.a.


05/12/16
20160129081 

Oral treatment of inflammatory bowel disease


Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from ibd in remission, prolong remission in said subject suffering from ibd, to reduce the occurrence of relapse in said subject suffering from ibd, or any combination thereof, is also described..
Defensin Therapeutics Aps


05/12/16
20160129054 

Process for the therapeutic management of diarrhea predominant irritable bowel syndrome using bacillus coagulans sbc-37-01, mtcc 5856


The present invention discloses a process for the therapeutic management of diarrhea predominant irritable bowel syndrome in humans comprising the oral administration of bacillus coagulans sbc37-01, mtcc 5856 (containing not less than 2 billion spores) along with standard treatment of care in a specific manner.. .

05/12/16
20160129039 

Process for the preparation of a non-corrosive base solution and methods of using same


The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production including, but not limited to, gout, lesch-nyhan syndrome, hemochromatosis, alzheimer's, amyotropic lateral sclerosis, arthritis, atherosclerosis, cancer, cataracts, chronic obstructive pulmonary disease, diabetes, cellulitis, coronary artery disease, heart failure, hypertension, inflammatory bowel disease, macular degeneration, multiple sclerosis, parkinson's, reynaud's phenomenon, reperfusion injury, pancreatic impairment, skin infections, hepatitis c, methicillin-resistant staphylococcus aureus and infection.

05/12/16
20160129031 

Pyrazole derivative and use thereof for medical purposes


The present invention provides pyrazole derivatives, uses thereof for medical purposes and so on. More particularly, the present invention relates to pharmaceuticals useful for the prevention or treatment of constipation, which comprise as an active ingredient 3-(3-{4-[3-(β-d-glucopyranosyloxy)-5-isopropyl-1h-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide, or a pharmaceutically acceptable salt thereof.
Kissei Pharmaceutical Co., Ltd.




Bowel topics: Bowel Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Inflammation, Mercaptopurine, Probiotics, Abdominal Pain, Discomfort, Bowel Movement, Gastrointestinal, Ulcerative Colitis, Rheumatoid Arthritis, Jejunal Tube, Spring Mechanism, Small Bowel

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9299

5641

469397 - 0 - 113